BioBetter

High-Level Overview

BioBetter is an Israeli agrobiotech startup founded in 2015 that develops a patent-protected platform using transgenic tobacco plants to produce complex proteins at dramatically lower costs than traditional methods.[1][2][3] The company serves the cultivated meat industry by manufacturing growth factors and bioactive proteins essential for cell-based meat production, while also targeting biopharmaceuticals, biosimilars, and cosmetics; it solves high manufacturing costs and scalability issues in biologics by turning plants into self-sustained bioreactors, enabling affordable, high-volume output.[1][2][4][5] With $15M raised and a new food-grade pilot facility launched in 2023 aiming for 5 tons annual production by 2025, BioBetter shows strong growth momentum in the molecular pharming space.[2]

Origin Story

BioBetter was founded in 2015 in Kiryat Shmona, Israel, by Oded Shoseyov, PhD—a professor of protein engineering and nano-biotechnology at Hebrew University with entrepreneurial experience; Dana Yarden, MD, MBA, a biotech business development expert and WuXi AppTec founding member in Israel; and Avi Tzur, an industrialist focused on repurposing tobacco positively.[1][3] The idea emerged from Shoseyov's research exploiting plants for protein production, addressing the need for cheaper biologics manufacturing amid high bioreactor costs; early traction included successfully producing Humira (a major antibody drug) and building capacity for biosimilars.[1] Key leaders like CEO Amit Yaari, with 10+ years in recombinant proteins from Collplant, and CRO Yonatan Eran have driven pivots toward cultivated meat growth factors, with pivotal moments like the 2023 pilot facility launch accelerating R&D.[1][2][5]

Core Differentiators

• Plant-based platform: Uses transgenic tobacco plants co-expressing target proteins with purification enzymes and Protein A-cellulose bridges, enabling in-planta purification that slashes costs, capital needs, and complexity versus bioreactors or clean rooms.[1][3][5]
• Cost and scalability: Produces proteins like growth factors for cultivated meat at a fraction of traditional prices; open-field cultivation potential offers limitless scale, targeting 100kg daily now and 5 tons by 2025.[2][5]
• Versatility and quality: Generates high-quality, food-grade bioactives for meat, pharma (e.g., Humira biosimilars), and cosmetics; extracts from plant chloroplasts yield superior, sustainable proteins.[2][4]
• Operational efficiency: Tools like Labguru streamline multi-lab collaboration, saving 50-60% time on documentation and coordination, boosting innovation speed.[5]

Role in the Broader Tech Landscape

BioBetter rides the molecular pharming and cultivated meat waves, leveraging gene-edited plants for sustainable protein production amid rising demand for animal-free alternatives.[2] Timing aligns with cultivated meat's commercialization push, where growth factor costs hinder scale; market forces like R&D investments, partnerships, and North American molecular pharming growth favor it.[2] By repurposing tobacco as bioreactors, BioBetter influences agrotech and foodtech ecosystems, lowering barriers for cultivated meat firms, supporting biosimilars access, and promoting Galilee-region jobs in inclusive AgriTech.[3][5]

Quick Take & Future Outlook

BioBetter is poised to dominate plant-derived growth factors, expanding from cultivated meat to integrated plant-animal protein matrices and cosmetics via exosomes.[2][4] Trends like gene editing advances and sustainability mandates will propel scaling, potentially capturing molecular pharming market share through open-field production.[2] Its influence may evolve into a key enabler for affordable biologics and cellular agriculture, transforming high-cost protein manufacturing into a democratized, earth-friendly process—echoing its founding mission to make life-changing proteins accessible worldwide.[1][3]